SI3643718T1 - Heterociklična spojina in njena uporaba kot pozitivni alosterični modulator holinergičnega muskarinskega receptorja M1 - Google Patents
Heterociklična spojina in njena uporaba kot pozitivni alosterični modulator holinergičnega muskarinskega receptorja M1Info
- Publication number
- SI3643718T1 SI3643718T1 SI201831003T SI201831003T SI3643718T1 SI 3643718 T1 SI3643718 T1 SI 3643718T1 SI 201831003 T SI201831003 T SI 201831003T SI 201831003 T SI201831003 T SI 201831003T SI 3643718 T1 SI3643718 T1 SI 3643718T1
- Authority
- SI
- Slovenia
- Prior art keywords
- receptor
- heterocyclic compound
- positive allosteric
- allosteric modulator
- cholinergic muscarinic
- Prior art date
Links
- 102000007207 Muscarinic M1 Receptor Human genes 0.000 title 1
- 108010008406 Muscarinic M1 Receptor Proteins 0.000 title 1
- 230000001713 cholinergic effect Effects 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 229940126027 positive allosteric modulator Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017120859 | 2017-06-20 | ||
| JP2018005960 | 2018-01-17 | ||
| US201862683418P | 2018-06-11 | 2018-06-11 | |
| PCT/JP2018/023357 WO2018235838A1 (ja) | 2017-06-20 | 2018-06-19 | 複素環化合物 |
| EP18819596.0A EP3643718B1 (en) | 2017-06-20 | 2018-06-19 | Heterocyclic compound and its use as positive allosteric modulator of the cholinergic muscarinic m1 receptor. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3643718T1 true SI3643718T1 (sl) | 2023-11-30 |
Family
ID=64737123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201831003T SI3643718T1 (sl) | 2017-06-20 | 2018-06-19 | Heterociklična spojina in njena uporaba kot pozitivni alosterični modulator holinergičnega muskarinskega receptorja M1 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11236099B2 (sl) |
| DK (1) | DK3643718T3 (sl) |
| ES (1) | ES2960408T3 (sl) |
| FI (1) | FI3643718T3 (sl) |
| HR (1) | HRP20231236T1 (sl) |
| HU (1) | HUE063823T2 (sl) |
| LT (1) | LT3643718T (sl) |
| MX (1) | MX2021015514A (sl) |
| PL (1) | PL3643718T3 (sl) |
| PT (1) | PT3643718T (sl) |
| RS (1) | RS64722B1 (sl) |
| SI (1) | SI3643718T1 (sl) |
| WO (1) | WO2018235838A1 (sl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3078164C (en) * | 2017-10-27 | 2022-11-15 | Suven Life Sciences Limited | Polycyclic amides as muscarinic m1 receptor positive allosteric modulators |
| WO2020067457A1 (ja) * | 2018-09-28 | 2020-04-02 | 武田薬品工業株式会社 | 縮合環化合物 |
| US11970483B2 (en) | 2018-09-28 | 2024-04-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2992677B2 (ja) | 1995-06-05 | 1999-12-20 | 武田薬品工業株式会社 | 骨形成促進医薬組成物 |
| GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
| JP4710445B2 (ja) * | 2004-07-08 | 2011-06-29 | 田辺三菱製薬株式会社 | 医薬組成物 |
| DK2512243T3 (en) | 2009-12-17 | 2016-07-25 | Merck Sharp & Dohme | POSITIVE ALLOSTERIC QUINOLINAMIDE M1 RECEPTOR MODULATORS |
| EP2582676B1 (en) | 2010-06-15 | 2016-12-14 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide m1 receptor positive allosteric modulators |
| EP2709621B1 (en) | 2011-05-17 | 2016-11-02 | Merck Sharp & Dohme Corp. | N-linked quinolineamide m1 receptor positive allosteric modulators |
| US9403802B2 (en) | 2012-03-02 | 2016-08-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use therefor |
| WO2014077401A1 (ja) | 2012-11-19 | 2014-05-22 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| NZ725921A (en) | 2014-04-23 | 2023-09-29 | Takeda Pharmaceuticals Co | Isoindoline-1-one derivatives as cholinergic muscarinic m1 receptor positive alloesteric modulator activity for the treatment of alzheimers disease |
| JP6531093B2 (ja) | 2014-05-16 | 2019-06-12 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| WO2015190564A1 (ja) | 2014-06-13 | 2015-12-17 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| WO2016009297A1 (en) | 2014-07-18 | 2016-01-21 | Pfizer Inc. | Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators |
| AU2016284654B9 (en) | 2015-06-26 | 2020-05-21 | Takeda Pharmaceutical Company Limited | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor |
| WO2017069173A1 (ja) | 2015-10-20 | 2017-04-27 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2017120859A (ja) | 2015-12-28 | 2017-07-06 | 帝人株式会社 | 組紐状圧電素子、組紐状圧電素子を用いた布帛状圧電素子およびそれらを用いたデバイス |
| CA3014791A1 (en) * | 2016-02-16 | 2017-08-24 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| WO2017155050A1 (ja) | 2016-03-11 | 2017-09-14 | 武田薬品工業株式会社 | 芳香環化合物 |
| JP2018005960A (ja) | 2016-07-01 | 2018-01-11 | エヌイーシー ショット コンポーネンツ株式会社 | 接触子を有する気密端子 |
| KR102017786B1 (ko) | 2016-09-02 | 2019-09-03 | 수벤 라이프 사이언시스 리미티드 | 무스카린 m1 수용체 포지티브 알로스테릭 조절제 |
| US10899759B2 (en) | 2016-09-30 | 2021-01-26 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 |
| EP3612527B1 (en) | 2017-04-18 | 2022-07-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds useful as modulators of acetylcholine receptors |
-
2018
- 2018-06-19 US US16/622,632 patent/US11236099B2/en active Active
- 2018-06-19 ES ES18819596T patent/ES2960408T3/es active Active
- 2018-06-19 HU HUE18819596A patent/HUE063823T2/hu unknown
- 2018-06-19 PT PT188195960T patent/PT3643718T/pt unknown
- 2018-06-19 SI SI201831003T patent/SI3643718T1/sl unknown
- 2018-06-19 FI FIEP18819596.0T patent/FI3643718T3/fi active
- 2018-06-19 DK DK18819596.0T patent/DK3643718T3/da active
- 2018-06-19 PL PL18819596.0T patent/PL3643718T3/pl unknown
- 2018-06-19 WO PCT/JP2018/023357 patent/WO2018235838A1/ja active Application Filing
- 2018-06-19 HR HRP20231236TT patent/HRP20231236T1/hr unknown
- 2018-06-19 RS RS20230955A patent/RS64722B1/sr unknown
- 2018-06-19 LT LTEPPCT/JP2018/023357T patent/LT3643718T/lt unknown
-
2019
- 2019-12-19 MX MX2021015514A patent/MX2021015514A/es unknown
-
2021
- 2021-09-15 US US17/475,733 patent/US20220017530A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021015514A (es) | 2022-02-22 |
| US11236099B2 (en) | 2022-02-01 |
| FI3643718T3 (fi) | 2023-11-01 |
| DK3643718T3 (da) | 2023-11-06 |
| LT3643718T (lt) | 2023-10-25 |
| US20220017530A1 (en) | 2022-01-20 |
| HUE063823T2 (hu) | 2024-02-28 |
| US20210139491A1 (en) | 2021-05-13 |
| PT3643718T (pt) | 2023-10-26 |
| RS64722B1 (sr) | 2023-11-30 |
| ES2960408T3 (es) | 2024-03-04 |
| HRP20231236T1 (hr) | 2024-02-16 |
| WO2018235838A1 (ja) | 2018-12-27 |
| PL3643718T3 (pl) | 2024-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286693A (en) | Combined stress response modulator compounds, preparations containing them and their uses | |
| ZA201808219B (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 | |
| LT3565550T (lt) | Farmacinės kompozicijos, apimančios meloksikamą ir rizatriptaną | |
| IL261058A (en) | Positive allosteric modulators of the muscarinic acetylcholine m1 receptor | |
| IL264951B (en) | Positive allosteric modulators of the m1 muscarinic receptor | |
| HK1253036A1 (zh) | 作為毒蕈碱m1和/或m4受體的激動劑的肟化合物 | |
| EP3558309A4 (en) | POSITIVE ALLOSTERIC MODULATORS OF THE ACETYLCHOLIN M4 MUSCARINIC RECEPTOR | |
| EP3534901A4 (en) | POSITIVE ALLOSTERIC MODULATORS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR | |
| EP3558946A4 (en) | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINE ACETYL CHOLINE RECEPTOR M4 | |
| EP3544961A4 (en) | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINE ACETYLCHOLINE RECEPTOR M4 | |
| IL255994B (en) | Positive allosteric am.1 muscarinic receptor modulators | |
| HK1247914A1 (zh) | 作為毒蕈鹼性m1受體正向別構調節劑的氟吲哚衍生物 | |
| PL3643718T3 (pl) | Związek heterocykliczny i jego zastosowanie jako dodatniego modulatora allosterycznego względem cholinergicznego receptora muskarynowego m1 | |
| ZA202002034B (en) | Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators | |
| EP3568137A4 (en) | HETEROCYCLIC COMPOUNDS AND USE OF SUCH COMPOUNDS | |
| ZA202102487B (en) | Pyrrolo-pyridazine derivatives as muscarinic m1 receptor positive allosteric modulators | |
| ZA202002938B (en) | Substituted azacycles as muscarinic m1 receptor positive allosteric modulators |